Volume 7, Issue 2

A case of figurate urticaria by etanercept

Maurizio Sessa, Maria Giuseppa Sullo, Annamaria Mascolo, Daniela Cimmaruta, Francesca Romano, Rosa Valentina Puca, Annalisa Capuano, Francesco Rossi, Ada Lo Schiavo

pp. 106–108 · DOI: 10.4103/0976-500X.184777 · Published 2016

Etanercept is a competitive inhibitor of tumor necrosis factor‑alpha (TNF‑α) a polypeptide hormone, involved in the development of the immune system, in host defense and immune surveillance. Even if the etanercept mechan…

Fixed drug eruption due to levocetirizine

Ratinder Jhaj, Dinesh Prasad Asati, Deepa Chaudhary

pp. 109–11 · DOI: 10.4103/0976-500X.184778 · Published 2016

A fixed drug eruption (FDE) is a cutaneous adverse drug reaction due to Type IV or delayed cell–mediated hypersensitivity. Antihistamines, which antagonize the action of histamine during an allergic reaction by blocking …

Acute hepatic injury with amphotericin B deoxycholate in an immunocompetent patient

Jamie L. Wagner, Allison M. Bell

pp. 112–114 · DOI: 10.4103/0976-500X.184779 · Published 2016

Amphotericin B deoxycholate (AmBd) is rarely used due to its adverse effect profile, which includes nephrotoxicity, infusion‑related reactions, and hepatotoxicity. The incidence of hepatotoxicity related to AmBd is 18–23…

Warfarin and phenytoin drug interaction with possible purple glove syndrome

Carolyn S. Hunter, Stephanie V. Phan

pp. 96–98 · DOI: 10.4103/0976-500X.184774 · Published 2016

Though the impact of phenytoin on warfarin has been reported to potentiate the anticoagulant effect or interact in a biphasic manner, the effect of phenytoin on warfarin appears to be unpredictable and dependent upon mul…

An unusual case of glipizide-induced proximal myopathy

Saibal Das, Anand Ramasamy, Soumyadip De, Somnath Mondal

pp. 99–101 · DOI: 10.4103/0976-500X.184775 · Published 2016

This case report outlines a very rare case of glipizide‑induced severe proximal myopathy in a 61‑year‑old diabetic man. After taking 10 mg glipizide for 5 months, diabetes was well controlled but the patient presented wi…

Expedited drug review process: Fast, but flawed

Krishnan Vengadaraga Chary

pp. 57–58 · DOI: 10.4103/0976-500X.184768 · Published 2016

L-asparaginase in the treatment of patients with acute lymphoblastic leukemia

Rachel A. Egler, Sanjay P. Ahuja, Yousif Matloub

pp. 62–71 · DOI: 10.4103/0976-500X.184769 · Published 2016

Acute lymphoblastic leukemia (ALL) is a hematologic malignancy that predominantly occurs in children between 2 and 10 years of age. L‑asparaginase is an integral component of treatment for patients with ALL and since its…

Factors influencing adherence to anti‑craving medications and drinking outcomes in patients with alcohol dependence: A hospital‑based study

K. Lohit, Chanda Kulkarni, R. B. Galgali

pp. 72–79 · DOI: 10.4103/0976-500X.184770 · Published 2016

Objective: To examine the factors influencing the pattern and extent of anti-craving medication adherence and drinking outcomes in alcohol-dependent patients. Materials and Methods: Demographic data from 102 inpatients w…

Effect of losartan and atenolol on insulin sensitivity in nondiabetic hypertensive patients

Sandesh Madhukar Bharati, Nishith Singh

pp. 80–86 · DOI: 10.4103/0976-500X.184771 · Published 2016

Objective: To study the effects of losartan and atenolol on glucometabolic parameters in nondiabetic hypertensive patients. Materials and Methods: In a prospective, open‑label, parallel group study, nondiabetic patients …

Is the peripheral arterial disease in low risk type 2 diabetic patients influenced by body mass index, lipidemic control, and statins?

Jayesh Dalpatbhai Solanki, Amit H. Makwana, Hemant B. Mehta, Pradnya A. Gokhale, Chinmay J. Shah

pp. 87–92 · DOI: 10.4103/0976-500X.184772 · Published 2016

Objective: To correlate BMI, lipidemic control, and statin therapy with PAD measured by ABI in low risk type 2 diabetics. Materials and Methods: A sample of 101 nonsmoking, asymptomatic type 2 diabetics (50 males, 51 fem…

A new mathematical approach to methadone conversion

Steven J. Baumrucker, Manar Jbara, Richard Marc Rogers

pp. 93–95 · DOI: 10.4103/0976-500X.184773 · Published 2016

For the past 20 years, methadone has been experiencing resurgence in the palliative care community as a second-line opioid for the treatment of cancer pain. Methadone is useful for refractory pain in cancer patients or i…